GC Genome

What GC Genome does

GC Genome Corporation is a clinical genomic diagnostics company established in 2013 as a subsidiary of South Korean healthcare conglomerate GC Group (Green Cross), headquartered in Yongin, Gyeonggi Province. It operates a CAP-accredited laboratory delivering genetic testing services across four core verticals: Pre & Neonatal Health (G-NIPT, i-screen), Health Checkup (Genome Health, Genome Screen, Greenbiome GUT, Pharmacogenetic Test, Telorisk), Precision Oncology (Women's, Hereditary, Solid Tumor, and Hematology Cancer Panels, Liquid Biopsy, HRD, and ai-CANCERCH), and Rare Disease (DES/WES/DGS, CMA, SMN1/2). Customers include Korean hospitals, research institutions, and patients served directly or through hospital partnerships, with international expansion via licensing partners in Thailand and the United States.

The company's core technology combines next-generation sequencing (NGS) with proprietary AI and deep learning algorithms applied to cell-free DNA (cfDNA) methylation, fragmentomics, and genomic features. Its flagship ai-CANCERCH test, commercially launched in September 2023, predicts the presence and tissue-of-origin of multiple cancer types (initially six, later expanded to nine) from a single blood draw. The underlying AI platform was developed in collaboration with KAIST and validated in Nature Communications at 91.1% sensitivity and 95% specificity across 2,543 cancer patient samples and 1,241 controls, with a 3,000+ patient Early Access Programme conducted during 2022-2023. Supporting proprietary assets include the cfWEMseq methylation sequencing workflow and the I-score genomic instability calculator derived from low-coverage whole-genome sequencing.

GC Genome operates a sales-led go-to-market model combining direct laboratory services to Korean healthcare providers with technology licensing and wet-lab know-how transfer to international partners such as MP Group (Thailand, exclusive license signed November 2023, commercialized as 'genechecks') and Genece Health (US, founded 2022 as a strategic spin-out partnership). Revenue derives from genetic testing service fees across all four verticals plus licensing/royalty income, with marketing centered on scientific conferences (ASCO, AACR, ESMO) and an active peer-reviewed publication record of 191 papers. The company is privately held with no venture capital or private equity funding rounds disclosed in available materials.

Name

GC Genome

Legal name

Green Cross Genome Inc.

Website

https://gc-genome.com

Company type

Private

Founded year

2013

Operating status

Operating

Short description

GC Genome is a South Korea-based clinical genomic diagnostics subsidiary of GC Group, operating a CAP-accredited laboratory that delivers genetic testing across prenatal, health checkup, precision oncology, and rare disease segments, with an AI-based multi-cancer early detection test (ai-CANCERCH) as its flagship offering.

Ownership category

akta.pro rank

Product category

Clinical Genomic Diagnostics

NAICS

Medical Laboratories (621511)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)

akta.pro secondary industries

Genetic & Prenatal Testing Laboratories (HLAFAMAH), Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD)

Keywords

• Clinical genomic diagnostics
• Genetic testing services
• Liquid biopsy diagnostics
• Non-invasive prenatal testing
• Precision oncology testing

Headquarters

HQ city

Yongin-si

HQ country

South Korea

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Genetic Testing Services: GC Genome generates revenue by providing genetic diagnosis services across four main areas: Pre&Neonatal Health, Health Checkup, Precision Oncology, and Rare Disease. Tests are offered to healthcare providers and patients, likely through laboratory service agreements and direct test ordering.
2. Technology Licensing and Transfer: GC Genome licenses its proprietary technologies (e.g., Genome Health SNP genotyping service) to international partners such as MP Group in Thailand, including transfer of wet lab know-how and operational capability to run a genetic laboratory.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

GC Genome operates a CAP-accredited clinical genomic diagnostics laboratory that processes genetic tests across four categories: Pre & Neonatal Health (NIPT, prenatal screening), Health Checkup (SNP genotyping, microbiome, pharmacogenetics), Precision Oncology (cancer panels, liquid biopsy, multi-cancer early detection via ai-CANCERCH), and Rare Disease (exome sequencing, chromosomal microarray, SMA testing). Tests are offered to healthcare providers, hospitals, and patients, with international commercialization through technology licensing and laboratory transfer partnerships.

Product overview

GC Genome is a clinical genomic diagnostics company offering a comprehensive portfolio of genetic testing services across four main categories: Pre & Neonatal Health (G-NIPT, i-screen), Health Checkup (Genome Health, Genome Screen, Greenbiome GUT, Pharmacogenetic Test, Telorisk), Precision Oncology (Women's Cancer Panel, Hereditary Cancer Panel, Solid Tumor Cancer Panel, Hematology Cancer Panel, Liquid Biopsy, HRD, ai-CANCERCH), and Rare Disease (DES/WES/DGS, CMA, SMN1/2). The company's flagship offering is ai-CANCERCH, an AI-powered liquid biopsy platform for multi-cancer early detection (MCED) that analyzes cell-free DNA using deep learning algorithms to detect and classify multiple cancer types from a single blood sample. GC Genome operates a CAP-accredited laboratory and leverages next-generation sequencing (NGS) technology for its diagnostic services.

Differentiator

Problem solved

Functional benefit

Products and services

• G-NIPT Non-invasive prenatal testing service that detects chromosomal conditions in fetuses by analyzing cell-free DNA from maternal blood samples. Intended for pregnant women and their healthcare providers.
• i-screen Pre & neonatal genetic screening service providing safe and accurate testing solutions for pregnant women during prenatal care.
• Genome Health SNP genotyping service utilizing next-generation sequencing to identify risk alleles associated with major cancer types and general diseases; analyzes 45 diseases in a single test for personalized health management.
• Genome Screen Genetic health checkup service providing disease-related genetic assessments for preventive healthcare and personalized health management.
• Greenbiome GUT Gut microbiome analysis service for health checkups, examining gut bacteria composition and its relationship to health conditions.
• Pharmacogenetic Test Genetic test analyzing how an individual's genetic makeup affects drug response and medication efficacy to guide personalized prescribing.
• Telorisk Telomere length analysis service for health assessment and aging-related risk evaluation.
• Women's Cancer Panel Multi-gene panel testing for hereditary cancers affecting women, including breast and ovarian cancer risk genes.
• Hereditary Cancer Panel Comprehensive hereditary cancer risk panel analyzing multiple genes associated with increased cancer susceptibility.
• Solid Tumor Cancer Panel Genomic profiling panel for solid tumor cancers that guides treatment decisions and identifies targeted therapies.
• Hematology Cancer Panel Genomic testing panel for hematologic malignancies including leukemia, lymphoma, and myeloma.
• Liquid Biopsy Non-invasive blood-based cancer testing using circulating tumor DNA (ctDNA) for cancer detection, monitoring, and treatment guidance.
• HRD (Homologous Recombination Deficiency) HRD testing service that identifies patients who may benefit from PARP inhibitors and other DNA repair-targeted therapies.
• ai-CANCERCH

Quantifiable outcome

• 91.1% sensitivity at 95% specificity and 81.7% accuracy in detecting cancer presence and predicting tissue-of-origin using AI-based liquid biopsy
• +3 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature6 records

Partnerships

Seven partnerships are on record, tiered core.

• Genece Health Inc. (San Diego, USA)coreStrategic or Co-development Partner · 7 May 2024Genece Health is a strategic partner founded in 2022 through a strategic partnership with GC Genome. The collaboration focuses on AI-based liquid biopsy technology for early cancer detection. GC Genome presented new clinical data on colorectal cancer detection using its AI-based liquid biopsy platform at the ASCO Annual Meeting 2024 through this collaborative effort. Genece leverages proprietary liquid biopsy and deep-learning AI technology and focuses on targeted screening and detection tools for high-mortality and women's health cancers.
• MP Group CO., LTD (Thailand)coreOEM/ Whitelabel/ Licensing Partner · 10 November 2023GC Genome entered an exclusive license and collaboration agreement with MP Group CO., LTD, headquartered in Bangkok, Thailand, to commercialize the 'Genome Health' SNP genotyping service for genetic health checkups. The agreement includes transfer of essential wet lab technology and know-how required to operate a genetic laboratory in Thailand. MP Group plans to launch the product under the name 'genechecks'. Additionally, GC Genome and MP Group signed an MoU to expand their partnership in Health Checkup, Pre&Neonatal Health, Precision Oncology, and Rare Diseases within Thailand, strengthening GC Genome's presence in the Southeast Asian healthcare market.
• KAIST (Korea Advanced Institute of Science and Technology)coreStrategic or Co-development Partner · 12 April 2023GC Genome collaborated with KAIST's Department of Bio and Brain Engineering to develop an AI-based liquid biopsy technology for multi-cancer early detection and tissue-of-origin localization. The research combined GC Genome's liquid biopsy technology with KAIST's deep learning algorithms, resulting in a Nature Communications publication in April 2023 demonstrating unprecedented accuracy with 91.1% sensitivity at 95% specificity.
• Samsung Medical CentercoreStrategic or Co-development PartnerGC Genome collaborated with Samsung Medical Center, Sungkyunkwan University School of Medicine, on a study demonstrating the feasibility of liquid biopsy technology using cfDNA I-score to predict radiation therapy response in solid tumors. The research was published in the Radiation Oncology Journal, expanding the clinical utility of GC Genome's genomic instability scoring platform.
• Kangbuk Samsung HospitalcoreStrategic or Co-development PartnerGC Genome collaborated with researchers at Kangbuk Samsung Hospital on a large-scale Korean population study linking gut microbiome composition to hypertension, published in Frontiers in Microbiomes. The study provided scientific evidence that modifying dietary habits to alter enterotypes could help prevent and manage hypertension.
• Severance Hospital (Yonsei University)coreStrategic or Co-development PartnerGC Genome collaborated with Dr. Joohyuk Sohn's team at Severance Hospital on a study published in the Journal of the National Cancer Institute demonstrating that ctDNA copy number aberration (CNA) burden can predict prognosis and guide molecular profiling in breast cancer patients.
• GC Corporation (GC group)coreOthersGC Genome was established in 2013 as a subsidiary (GC company) of GC Corporation (Green Cross Corp), a prominent healthcare organization in South Korea. GC Genome operates as the genomics arm of GC Corporation, leveraging the parent company's infrastructure, brand, and healthcare ecosystem. The broader GC Family includes entities across pharmaceuticals (GC Biopharma), healthcare (GC Wellbeing, GC Care), diagnostics (GCMS, GC Medis, GCCL), and other life sciences companies globally.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Macrogen: Korea-based genomic services company offering NGS-based sequencing, clinical diagnostics, and precision medicine services. Directly comparable as a Korean-headquartered clinical genomics laboratory with overlapping capabilities in cancer panels, rare disease testing, and NIPT.
• Natera: US-based genetic testing company specializing in NIPT (Panorama), oncology liquid biopsy (Signatera), and transplant diagnostics. Directly comparable across GC Genome's pre/neonatal health and precision oncology segments with similar cfDNA-based testing approaches.
• GRAIL: US-based multi-cancer early detection (MCED) company developing the Galleri test for early detection of multiple cancers via cfDNA methylation analysis. The most direct competitor to GC Genome's ai-CANCERCH liquid biopsy MCED platform with similar technological approach.
• Myriad Genetics: US-based genetic testing company with strong hereditary cancer (BRACAnalysis) and oncology panels. Comparable across GC Genome's hereditary cancer panel, women's cancer panel, and pharmacogenetic testing offerings.
• NeoGenomics: US-based oncology-focused clinical laboratory offering comprehensive genomic profiling, liquid biopsy, and hereditary cancer testing. Comparable across GC Genome's precision oncology portfolio including solid tumor panels, hematology panels, and hereditary cancer testing.
• Invitae: US-based medical genetics company offering hereditary cancer testing, rare disease diagnostics, and reproductive health testing. Comparable across GC Genome's hereditary cancer panels, rare disease (DES/WES/DGS), and reproductive health (NIPT) segments.

Broad incumbents

• Guardant Health: US-based liquid biopsy leader offering Guardant360 for comprehensive genomic profiling and Reveal for MRD detection. Overlaps with GC Genome's liquid biopsy and Precision Oncology segments as a more established, broader-platform competitor.
• Foundation Medicine: US-based molecular profiling company (Roche subsidiary) offering comprehensive genomic profiling for solid tumors and hematologic malignancies. Comparable as a larger established player in tumor genomic profiling with overlapping solid tumor and hematology cancer panel offerings.
• Exact Sciences: US-based cancer screening and diagnostics company with Cologuard (colorectal) and Oncotype DX, plus emerging MCED efforts. Comparable as a larger established oncology diagnostics player with overlapping liquid biopsy and cancer screening ambitions.

Emerging players

• Personalis: US-based genomics company specializing in ultra-sensitive cancer genomics via ImmunoID Next platform for tumor profiling and MRD detection. Comparable as an emerging player in deep genomic analysis with overlap in liquid biopsy methodology.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GC Genome